Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma
Source: Onc Live, July 2022
Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.
